Hurley Capital’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Hurley Capital’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$12	–	714
2026 Q1	$12	Hold	1	–	–	﹤0.01%	663
2025 Q4	$405	Hold	1	–	–	﹤0.01%	550
2025 Q3	$197	Hold	1	–	–	﹤0.01%	656
2025 Q2	$200	Hold	1	–	–	﹤0.01%	441
2025 Q1	$161	Hold	1	–	–	﹤0.01%	479
2024 Q4	$236	Buy	+1	New	+$300	﹤0.01%	386

Other funds holding IRLA

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Hurley Capital's IRLA Position: Q2 2026 in Review

Hurley Capital sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 1 share — an estimated $12 sold.

Hurley Capital first reported a position in IRLA in Q4 2024 and held it in 6 quarters. The position peaked at $405 in Q4 2025. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

Hurley Capital reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
Hurley Capital sold 1 IRulya Therapeutics Inc. Common Stock share in Q2 2026, an estimated $12.
Hurley Capital first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2024 and held it in 6 quarters.
Hurley Capital's IRulya Therapeutics Inc. Common Stock position peaked at $405 in Q4 2025.
26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.